Semax

Background

Semax is a synthetic heptapeptide analog of adrenocorticotropic hormone (ACTH) with the sequence Met–Glu–His–Phe–Pro–Gly–Pro, corresponding to ACTH(4–7) extended by a C‑terminal Pro‑Gly‑Pro (PGP) tripeptide.[11][13][15] It is often denoted ACTH(4–7)PGP. Semax was developed in Russia in the late 1980s–1990s as a melanocortin‑derived neuropeptide with enhanced metabolic stability and central activity.[11][13][15] The PGP motif is a glyproline fragment that confers resistance to peptidase degradation and contributes to regulatory activity.[15]

Semax is classified pharmacologically as a nootropic and neuroprotective peptide. It has been approved and widely used in the Russian Federation and some neighboring countries for the treatment of acute ischemic stroke and various cognitive and neuropsychiatric conditions, typically administered as intranasal drops.[11][13][15] Outside the former Soviet Union, Semax remains an investigational or off‑label agent, with limited recognition by Western regulatory agencies.

Mechanism of action

Semax is derived from the ACTH(4–7) fragment, which is known to interact with the melanocortin system, but Semax does not exhibit classical glucocorticoid‑stimulating endocrine activity.[11][13] Its mechanisms are predominantly neurotrophic, neuromodulatory, and anti‑inflammatory, rather than endocrine.

Key mechanistic features include:

• Regulation of neurotrophin expression

  • In rat models of permanent middle cerebral artery occlusion (pMCAO), Semax markedly upregulates Bdnf, Ngf, Ntf3, and Ntf5 transcription in the ischemic cortex.[12]
  • Semax also increases mRNA for neurotrophin receptors (e.g., Ntrk2/TrkB, Ngfr/p75NTR) selectively in the ischemic cortex, suggesting a coordinated activation of neurotrophic signaling.[12]

• Modulation of inflammatory and stress‑response genes

  • Transcriptomic analyses in rat cerebral ischemia–reperfusion show that Semax downregulates pro‑inflammatory and stress‑related genes (including those linked to cytokine signaling and apoptosis) and upregulates genes associated with recovery and synaptic function.[11][13][15]
  • Pathway enrichment indicates suppression of MAPK/JNK signaling, matrix metalloproteinases (e.g., MMP‑9), and immediate‑early genes such as c‑Fos, which are implicated in neuronal injury.[13]

• Protein‑level effects and signaling pathways

  • Proteomic profiling of brain tissue after transient focal ischemia in rats demonstrates Semax‑induced shifts in expression of proteins involved in synaptic transmission, cytoskeleton, energy metabolism, and redox balance, consistent with neuroprotection.[11][13]
  • Western blot analyses show downregulation of active JNK, reduced MMP‑9 levels, and decreased c‑Fos protein expression in ischemic regions after Semax treatment.[13]

• Interaction with amyloid and metal ions

  • In vitro studies demonstrate that Semax forms stable complexes with Cu²⁺ and inhibits copper‑induced aggregation of amyloid‑β (Aβ), reducing fibrillogenesis and oligomer formation in artificial membrane models.[14]
  • Semax reduces Aβ‑induced toxicity in cell‑based MTT assays, suggesting potential relevance to amyloidogenic neurodegenerative processes.[14]

• Glyproline component and stability

  • The PGP glyproline motif is associated with resistance to proteolysis and can modulate inflammatory and vascular responses.[15] PGP and related glyprolines act as endogenous regulatory peptides with roles in chemoattraction and vascular protection, and this motif is proposed to contribute to Semax’s prolonged activity and anti‑inflammatory properties.[15]

Receptor‑level targets for Semax remain incompletely defined. While derived from an ACTH fragment that interacts with melanocortin receptors (MC1R–MC5R), direct binding data for Semax to specific receptor subtypes are limited in the accessible literature, and many effects appear to be mediated through downstream gene‑expression reprogramming rather than a single identified receptor.[11][12][13]

Evidence summary

Preclinical evidence

Ischemic stroke models

• Cerebral ischemia–reperfusion in rats

  • A proteomic study using rat middle cerebral artery occlusion with reperfusion evaluated brain protein expression after Semax administration.[11][13]
  • Semax treatment reduced expression of proteins associated with inflammation, oxidative stress, and apoptosis, and increased proteins involved in neuroplasticity and metabolic recovery.[11][13]
  • The study reported attenuation of infarct‑associated signaling (downregulation of MMP‑9, c‑Fos, active JNK) and supported functional neuroprotection, although detailed behavioral outcomes are only partially described.[13]

• Transcriptomic analyses in ischemia–reperfusion

  • A study of glyproline peptides in rat cerebral ischemia–reperfusion compared Semax and related peptides on cortical gene expression.[15]
  • Semax preserved or normalized expression of genes involved in neurotransmission, neurotrophic signaling, and inflammatory regulation, indicating a broad neuroprotective genomic response.[15]

• Neurotrophin gene activation after cerebral ischemia

  • In rats subjected to pMCAO, Semax markedly upregulated Bdnf, Ngf, Ntf3, Ntf5 and their receptors in the ischemic cortex but not in non‑ischemic or sham‑operated controls, suggesting context‑dependent activation.[12]

Amyloid and neurodegeneration‑related models

• An in vitro study assessed Semax in Aβ–Cu²⁺ aggregation systems and artificial membranes.[14]
  • Semax bound Cu²⁺, inhibited formation of Aβ–Cu²⁺ complexes, reduced Aβ fibril formation, and decreased oligomer‑associated toxicity in neuronal cell lines.[14]
  • These findings indicate anti‑aggregating and metal‑chelation properties that may be relevant to Alzheimer‑type pathology, though in vivo neurodegeneration data are limited.

Clinical evidence

Semax has been used clinically in Russia for acute ischemic stroke and cognitive indications, but much of the clinical literature is in Russian and not comprehensively indexed in major Western databases. The accessible English‑language literature and reviews frequently refer to clinical use in stroke, but detailed randomized controlled trials with full methodology and sample sizes are not consistently available in PubMed‑indexed sources.[11][12][13][15]

Key points from available clinical‑oriented sources:

• Reviews and experimental papers describe Semax as being “used in the treatment of ischemic stroke” in Russia, administered during the acute phase via intranasal route.[11][13][15]
• Reported clinical outcomes in local literature (not fully accessible in English) include improvement in neurological deficit scores and functional recovery, but these data cannot be independently evaluated from the currently available indexed sources.
• No phase 2/3 randomized, placebo‑controlled trials in stroke meeting contemporary Western trial reporting standards were identified in ClinicalTrials.gov or major English‑language databases.

Consequently, the strongest evidence base is preclinical, with limited, region‑specific clinical data and minimal integration into Western stroke or neurology guidelines.

Clinical and research uses

Approved or routine uses (Russia and some CIS countries)

Based largely on Russian regulatory practice and local clinical experience, Semax is used for:

• Acute ischemic stroke (as a neuroprotective adjunct during the acute and early recovery period).[11][13][15]
• Cognitive impairment and nootropic indications, such as cognitive dysfunction, attention deficits, and certain neuropsychiatric conditions (based on regional sources cited in preclinical papers).[11][15]

These uses are region‑specific and are not endorsed by US or EU regulatory agencies.

Investigational uses

Preclinical and mechanistic data support investigation of Semax in:

• Ischemic stroke and cerebral ischemia–reperfusion injury (neuroprotection, plasticity enhancement).[11][12][13][15]
• Neurodegenerative diseases with amyloid pathology and metal dysregulation, such as Alzheimer’s disease, based on Aβ–Cu²⁺ aggregation inhibition and neuroprotection in vitro.[14]
• Inflammation‑associated neurological injury, given its modulation of inflammatory and neurosignaling gene networks.[11][12][15]

However, there is limited formal clinical trial activity in these areas in internationally visible registries.

Dosing context

Semax is marketed in Russia primarily as intranasal drops, which facilitates central nervous system exposure by partial nose‑to‑brain delivery. Experimental and clinical reports typically describe short‑course dosing in the acute phase of neurological injury.[11][13][15]

• In rodent models of cerebral ischemia, Semax is administered at doses in the microgram per kilogram range by intranasal or parenteral routes, often repeated over several days after ischemic onset.[11][12][15]
• Clinical practice descriptions from Russian literature (summarized in preclinical reviews) refer to multiple daily intranasal doses over 5–10 days for acute stroke and shorter courses for cognitive indications, but exact human dose regimens vary by product formulation and are not standardized across sources.[11][15]

Specific human dose amounts are not detailed in the indexed English‑language primary literature used here, and any dosing in practice should be regarded as region‑specific and not generalizable. No approved dosing regimens exist in US/EU.

Safety profile

Preclinical safety and tolerability

Animal studies indicate that Semax is generally well tolerated at neuroprotective doses.

• In rat cerebral ischemia models, Semax did not exacerbate infarct size or induce overt systemic toxicity; rather, it attenuated molecular markers of injury.[11][13][15]
• In vitro cell‑based assays used to evaluate Semax’s anti‑amyloid effects showed no intrinsic cytotoxicity at concentrations effective in preventing Aβ–Cu²⁺ toxicity.[14]

Clinical safety (regional experience)

Accessible experimental and review articles referencing clinical use describe Semax as a “neuroprotective drug” with an established safety profile in Russian practice, but systematic adverse‑event reporting is sparse in internationally indexed literature.[11][13][15]

Reported or inferred tolerability features include:

• Local tolerability: Intranasal administration is generally considered to have low systemic adverse effects; local irritation or discomfort is possible but not well quantified.
• Lack of endocrine side‑effects: Owing to its design, Semax does not exhibit the corticosteroidogenic effects typical of full‑length ACTH, and endocrine adverse events are not prominent in available reports.[11][13]

However, the absence of large, rigorously reported clinical trials limits robust characterization of rare or long‑term adverse events.

Contraindications and precautions

Formal contraindication profiles from regulatory documents are not available in US/EU sources. Based on its pharmacology and route of administration, plausible concerns include:

• Hypersensitivity to peptide components or excipients.
• Caution in individuals with severe allergic or immune‑mediated conditions, given immunogenic potential of peptide drugs (although specific data are lacking).

Definitive contraindication lists and risk profiles are largely confined to regional product information not fully indexed in Western databases.

Regulatory status

• Russian Federation and some CIS countries: Semax is approved as a prescription neuropeptide drug for acute ischemic stroke and certain cognitive/neuropsychiatric indications, marketed in intranasal formulations.[11][13][15] It is regarded locally as a standard neuroprotective adjunct in stroke care.

• United States:

  • Semax is not approved by the US Food and Drug Administration (FDA) for any indication.
  • No active, FDA‑registered investigational new drug (IND) programs or phase 2/3 clinical trials involving Semax were identified in internationally accessible registries.

• European Union:

  • Semax is not authorized as a medicinal product by the European Medicines Agency (EMA) for any indication.
  • It does not appear in EMA public assessment reports or centralized procedure documents.

Accordingly, in US and EU jurisdictions, Semax should be considered an unapproved, investigational peptide, with use restricted to research settings or unregulated markets. Clinical claims of efficacy and safety are primarily based on regional experience and preclinical data, rather than globally accepted regulatory standards.